Landscape of targeted therapies for advanced urothelial carcinoma.

Content Provider	Europe PMC
Author	Shang, Shihao Zhang, Lei Liu, Kepu Lv, Maoxin Zhang, Jie Ju, Dongen Wei, Di Sun, Zelong Wang, Pinxiao Yuan, Jianlin Zhu, Zheng
Editor	Normanno, Nicola
Abstract	Bladder cancer (BC) is the tenth most common malignancy globally. Urothelial carcinoma (UC) is a major type of BC, and advanced UC (aUC) is associated with poor clinical outcomes and limited survival rates. Current options for aUC treatment mainly include chemotherapy and immunotherapy. These options have moderate efficacy and modest impact on overall survival and thus highlight the need for novel therapeutic approaches. aUC patients harbor a high tumor mutation burden and abundant molecular alterations, which are the basis for targeted therapies. Erdafitinib is currently the only Food and Drug Administration (FDA)-approved targeted therapy for aUC. Many potential targeted therapeutics aiming at other molecular alterations are under investigation. This review summarizes the current understanding of molecular alterations associated with aUC targeted therapy. It also comprehensively discusses the related interventions for treatment in clinical research and the potential of using novel targeted drugs in combination therapy.
Related Links	https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC11220318&blobtype=pdf
Volume Number	5
DOI	10.37349/etat.2024.00240
PubMed Central reference number	PMC11220318
Issue Number	3
PubMed reference number	38966172
Journal	Exploration of Targeted Anti-tumor Therapy [Explor Target Antitumor Ther]
e-ISSN	26923114
Language	English
Publisher	Open Exploration Publishing
Publisher Date	2024-06-21
Access Restriction	Open
Rights License	This is an Open Access article licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. © The Author(s) 2024.
Subject Keyword	Bladder cancer advanced urothelial carcinoma targeted therapy combination therapy molecular alteration
Content Type	Text
Resource Type	Article
Subject	Oncology Cancer Research